Edited Jame Abraham

Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer

Uridine triacetate provides antidote for 5-fluorouracil overdose and toxicity

Trabectedin expands treatment options for some forms of advanced soft tissue sarcoma

More success for immunotherapy with nivolumab approval for metastatic RCC

Encapsulated irinotecan provides novel option for hard-to-treat pancreatic cancer

Second targeted combination regime approved for metastatic melanoma

Idarucizumab given the nod as the first specific antidote for an oral anticoagulant

Filgrastim-sndz debuts as the first biosimilar approved in United States

Approval reinstates gefitinib as a therapy for lung cancer

Dinutuximab combination therapy becomes first approval for high-risk neuroblastoma

Nivolumab: first immunotherapy approved for lung cancer

Olaparib for BRCA-mutated advanced ovarian cancer

Blinatumomab for hard-to-treat form of acute lymphoblastic leukemia

Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer

Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression

Edited Jame Abraham

Pages